News

Benchmark Initiates Coverage of Interface (TILE) with Buy Recommendation

TILE

Fintel reports that on May 19, 2026, Benchmark initiated coverage of Interface (NasdaqGS:TILE) with a Buy recommendation. Analyst Price Forecast Suggests 37.89% Upside

Wolfe Research Initiates Coverage of Tyra Biosciences (TYRA) with Peer Perform Recommendation

TYRA

Fintel reports that on May 19, 2026, Wolfe Research initiated coverage of Tyra Biosciences (NasdaqGS:TYRA) with a Peer Perform recommendation. Analyst Price Forecast Suggests 52.23% Upside

Wolfe Research Initiates Coverage of Oklo (OKLO) with Peer Perform Recommendation

OKLO

Fintel reports that on May 19, 2026, Wolfe Research initiated coverage of Oklo (NYSE:OKLO) with a Peer Perform recommendation. Analyst Price Forecast Suggests 69.27% Upside

Alliance Global Partners Initiates Coverage of NeOnc Technologies Holdings (NTHI) with Buy Recommendation

NTHI

Fintel reports that on May 19, 2026, Alliance Global Partners initiated coverage of NeOnc Technologies Holdings (NasdaqGM:NTHI) with a Buy recommendation. Analyst Price Forecast Suggests 178.18% Upside

Canaccord Genuity Upgrades Progyny (PGNY)

PGNY

Fintel reports that on May 19, 2026, Canaccord Genuity upgraded their outlook for Progyny (NasdaqGS:PGNY) from Hold to Buy. Analyst Price Forecast Suggests 16.83% Upside

Asia markets poised for mixed open amid spike in Treasury yields, Iran tensions

Asia-Pacific markets were poised to open mixed on Wednesday as investors weighed elevated bond yields and renewed geopolitical tensions.

Adverts for DNA self-swab kits banned as misleading

The Advertising Standards Authority has ruled Enough's online posts contained unproven claims.

UK should set maximum working temperature rules, advisers say

Successive governments have failed to prepare the UK for extreme heat, the climate watchdog says.

Wolfe Research Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Outperform Recommendation

MIRM

Fintel reports that on May 19, 2026, Wolfe Research initiated coverage of Mirum Pharmaceuticals (NasdaqGM:MIRM) with a Outperform recommendation. Analyst Price Forecast Suggests 56.11% Upside

Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Neutral Recommendation

BBIO

Fintel reports that on May 19, 2026, Citigroup initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Neutral recommendation. Analyst Price Forecast Suggests 59.71% Upside